IL6 and neoplasm: The partial response to a leptin-blocking peptide is in agreement with Coward and colleagues’ finding that siltuximab treatment (an anti-IL6 antibody) significantly reduces tumor burden, but does not completely eliminate metastatic foci and ascites accumulation in xenograft mouse models [55].